Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Aged
Body Mass Index
Diabetes Mellitus, Type 2
/ blood
Female
Glucosides
/ therapeutic use
Glycated Hemoglobin
/ metabolism
Glycemic Control
Humans
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ complications
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Thiophenes
/ therapeutic use
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
26
12
2020
received:
08
10
2020
accepted:
18
01
2021
pubmed:
25
9
2021
medline:
5
3
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
Sodium glucose cotransporter-2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was conducted in patients with type 2 diabetes with NAFLD. The changes in glycemic control, obesity, and liver pathology were compared between participants taking ipragliflozin (50 mg/day for 72 weeks; IPR group) and participants being managed without SGLT2is, pioglitazone, glucagon-like peptide-1 analogs, or insulin (CTR group). In the IPR group (n = 25), there were significant decreases in hemoglobin A1c (HbA1c) and body mass index (BMI) during the study (HbA1c, -0.41%, P < 0.01; BMI, -1.06 kg/m
Identifiants
pubmed: 34558835
doi: 10.1002/hep4.1696
pmc: PMC8710792
doi:
Substances chimiques
Glucosides
0
Glycated Hemoglobin A
0
Sodium-Glucose Transporter 2 Inhibitors
0
Thiophenes
0
hemoglobin A1c protein, human
0
ipragliflozin
3N2N8OOR7X
Banques de données
UMIN-CTR
['UMIN000015727']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
120-132Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.
Références
Diabetes Technol Ther. 2011 Dec;13(12):1219-27
pubmed: 21854192
J Hepatol. 2008 May;48(5):829-34
pubmed: 18321606
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Int J Mol Sci. 2019 Dec 26;21(1):
pubmed: 31888083
Diabetes Care. 2014 Oct;37(10):2864-83
pubmed: 25249672
J Hepatol. 2018 Feb;68(2):335-352
pubmed: 29122390
J Hepatol. 2014 Jan;60(1):110-7
pubmed: 23978719
Diabetologia. 2018 Oct;61(10):2155-2163
pubmed: 30066148
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
Radiology. 1999 Apr;211(1):283-6
pubmed: 10189485
Hepatol Res. 2019 Jan;49(1):64-71
pubmed: 30051943
Nat Med. 2015 May;21(5):512-7
pubmed: 25894829
Diabetes Obes Metab. 2019 Apr;21(4):812-821
pubmed: 30447037
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Diabetes Care. 2018 Feb;41(2):372-382
pubmed: 29358469
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Hepatology. 2017 May;65(5):1557-1565
pubmed: 28130788
Diabetes Metab Res Rev. 2013 Jul;29(5):406-12
pubmed: 23508966
Diabetes Obes Metab. 2015 Mar;17(3):304-8
pubmed: 24919820
J Hepatol. 2008 May;48(5):821-8
pubmed: 18329127
Expert Opin Pharmacother. 2016 Oct;17(15):1985-94
pubmed: 27463414
Diabetologia. 2020 Feb;63(2):221-228
pubmed: 31853556
Hepatol Res. 2019 May;49(5):531-539
pubmed: 30577089
Diabetes Res Clin Pract. 2018 Jan;135:178-184
pubmed: 29162514
Front Endocrinol (Lausanne). 2018 Nov 06;9:649
pubmed: 30459715
J Gastroenterol. 2015 Jan;50(1):76-84
pubmed: 24603981
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Hepatology. 2016 Nov;64(5):1577-1586
pubmed: 27543837
Gastroenterology. 1999 Jun;116(6):1413-9
pubmed: 10348825
Dig Dis Sci. 2020 Feb;65(2):623-631
pubmed: 30684076
Diabetes Care. 1996 Oct;19(10):1138-41
pubmed: 8886564
Am J Physiol Gastrointest Liver Physiol. 2016 Jan 15;310(2):G117-27
pubmed: 26564716
Am J Gastroenterol. 1999 Sep;94(9):2467-74
pubmed: 10484010
J Clin Invest. 1992 Oct;90(4):1323-7
pubmed: 1401068
Semin Diagn Pathol. 2006 Aug-Nov;23(3-4):149-60
pubmed: 17355088
PLoS One. 2016 Mar 15;11(3):e0151511
pubmed: 26977813
J Hepatol. 1996 Feb;24(2):148-54
pubmed: 8907567
Biomed Pharmacother. 2018 Sep;105:1033-1041
pubmed: 30021338
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
Biochem Biophys Res Commun. 2017 Nov 4;493(1):40-45
pubmed: 28928093
Diabetes Res Clin Pract. 2018 Aug;142:254-263
pubmed: 29859912
Circulation. 2018 Jan 23;137(4):323-334
pubmed: 29133604
Hepatology. 2011 Feb;53(2):448-57
pubmed: 21274866
Nature. 2020 Mar;579(7798):279-283
pubmed: 32132708
PLoS One. 2016 Jan 05;11(1):e0146337
pubmed: 26731267
Diabetes Ther. 2018 Feb;9(1):285-295
pubmed: 29322486
J Pharm Pharm Sci. 2018;21(1):222-235
pubmed: 29935547
Sci Rep. 2019 Oct 14;9(1):14754
pubmed: 31611596
Can J Physiol Pharmacol. 2018 Jun;96(6):587-596
pubmed: 29406832
Diabetes Obes Metab. 2018 Feb;20(2):438-442
pubmed: 28719078